Kevin S Orwig
USPTO Patent Examiner·Active 2019 to 2026
Kevin S Orwig is a USPTO patent examiner who has handled 14 ex parte reexaminations between 2019 and 2026, with 7 currently open. These reexams concentrate in Chemistry & Materials, Life Sciences & Consumer, and Mechanical & Manufacturing. ExamPat indexes the full prosecution record for each of these cases, including office-action grounds, certificate outcomes, and downstream PTAB and federal-circuit decisions.
Filings by year
Technology mix
Compare against all examiners
Eight side-by-side metrics: case volume, pendency, OAs per reexam, rejection mix, SNQ denial rate, certification rate, and PTAB appeal rate, with a Δ column showing where this examiner runs higher or lower than the corpus.
- Average and median pendency, both for this examiner and the corpus
- Rejection basis split (102 / 103 / 112) head-to-head
- Certification, SNQ denial, and PTAB appeal rates
Certificate outcome distribution
How this examiner's certificates split across the six possible outcomes: all claims confirmed, confirmed with amendment, confirmed with new claims, mixed, or all claims canceled. Includes share comparison to the corpus distribution.
- Count and share for each of the six outcome buckets
- Δ vs. corpus distribution in percentage points
- Useful for setting realistic patent-owner expectations
Event-to-event timing
Median time for this examiner's cases at each prosecution stage, from filing to first office action, filing to NIRC, and filing to certificate, with corpus comparison and sample size.
- Median in months per transition
- Side-by-side with the corpus median
- n column showing how many of this examiner's cases completed each transition
vs. all examiners
Certificate outcome distribution
Event-to-event timing (median)
Recent reexaminations (14)
| Control # | Filed | Patent | Title | Pendency | Status |
|---|---|---|---|---|---|
| 90/016,154 | Apr 3, 2026 | 12,151,003 | Stable, concentrated radionuclide complex solutions | — | Open |
| 90/016,039 | Mar 11, 2026 | 12,168,063 | Stable, concentrated radionuclide complex solutions | — | Open |
| 90/015,784 | Dec 15, 2025 | 12,151,863 | PUSH THROUGH BLISTER PACKAGE WITH PLASTIC LIDDING | — | Open |
| 90/015,652 | Oct 30, 2025 | 12,151,863 | PUSH THROUGH BLISTER PACKAGE WITH PLASTIC LIDDING | — | Open |
| 90/015,636 | Oct 24, 2025 | 11,203,748 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN | — | Open |
| 90/019,884 | Mar 18, 2025 | 8,114,426 | GRANULAR TURF SAFE MESOTRIONE COMPOSITIONS | 11 mo | Closed |
| 90/019,692 | Oct 3, 2024 | 11,033,495 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | 10 mo | Closed |
| 90/019,548 | Jun 25, 2024 | 10,865,441 | Mutant Taq Polymerase for Faster Amplification | 13 mo | Closed |
| 90/019,516 | May 21, 2024 | 10,392,438 | BISPECIFIC ANTIBODIES | — | Open |
| 90/019,502 | May 2, 2024 | 11,365,394 | ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF | 17 mo | Closed |
| 90/019,310 | Nov 29, 2023 | 9,596,871 | Canola Germplasm Exhibiting Seed Compositional Attributes That Deliver Enhanced Canola Meal Nutritional Value | — | Open |
| 90/015,080 | Jul 26, 2022 | 7,064,197 | SYSTEM, ARRAY AND NON-POROUS SOLID SUPPORT COMPRISING FIXED OR IMMOBILIZED NUCLEIC ACIDS | 40 mo | Closed |
| 90/014,270 | Feb 26, 2019 | 7,064,197 | System, Array and Non-Porous Solid Support Comprising Fixed or Immobilized Nucleic Acids | 81 mo | Closed |
| 90/014,272 | Feb 26, 2019 | 7,064,197 | SYSTEM, ARRAY AND NON-POROUS SOLID SUPPORT COMPRISING FIXED OR IMMOBILIZED NUCLEIC ACIDS | 81 mo | Closed |
Get the full reexam analytics
Compare Kevin S Orwig against the full corpus, see the certificate-outcome split, drill into event timing, filter the case list, and export. Free to sign up.